- Author:
Na Ri SHIN
1
;
Yoo Young LEE
;
Seung Hyun KIM
;
Chel Hun CHOI
;
Tae Joong KIM
;
Jeong Won LEE
;
Duk Soo BAE
;
Byoung Gie KIM
Author Information
- Publication Type:Original Article
- Keywords: Anemia; Hemoglobins; Prognosis; Survival; Uterine cervical neoplasms
- MeSH: Anemia; Disease-Free Survival; Gynecology; Humans; Hysterectomy; Korea; Multivariate Analysis; Obstetrics; Prognosis; Retrospective Studies; Seoul; Uterine Cervical Neoplasms*
- From:Obstetrics & Gynecology Science 2014;57(1):28-36
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: The purpose of this study is to investigate the prognostic role of pretreatment anemia in patients with early cervical cancer who underwent radical hysterectomy. METHODS: In this study, we retrospectively enrolled patients with early cervical cancer (International Federation of Obstetrics and Gynecology stage IB to IIA) who were treated at Samsung Medical Center, Seoul, Korea, from 1996 to 2007. RESULTS: We retrospectively enrolled 805 patients. Median pretreatment hemoglobin (Hb) level was 12.8 g/dL (4.0-16.9) in all patients. Ninety-ninth out of 805 patients had pretreatment anemia (12.3%). Pretreatment anemia was significantly associated with large tumor size, advanced clinical stage, and parametrial invasion. In multivariate analysis, higher pretreatment Hb entailed better prognostic significance in disease free survival (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.078-0.99) but not in overall survival (HR, 0.94; 95% CI, 0.80-1.10). CONCLUSION: In conclusion, we found that the negative association between pretreatment Hb level and tumor size and the impact of anemia before treatment on disease free survival adjusted for other factors including clinical stage and pathological findings in early stage cervical cancer.